Kronos raises $18M seed round, names Bischofberger CEO

Cancer company Kronos Bio Inc. (New York, N.Y.) raised $18 million in seed financing May 23 and hired Norbert Bischofberger as president and CEO. Bischofberger was EVP of R&D and CSO of Gilead Sciences Inc. (NASDAQ:GILD) until April.

Two River led the round. That firm's partner and chairman, Arie Belldegrun, was chairman, president and CEO of Kite Pharma Inc. prior to its sale to Gilead last year. He is Kronos' chairman...